芬吗通连续序贯治疗121例更年期综合征临床疗效的观察

目的 探讨应用芬吗通连续序贯给药治疗更年期综合征的临床疗效与安全性。方法 以2014年1月-2015年10月本院专家门诊收治的121例更年期综合征患者为对象，采用芬吗通进行激素替代治疗24周，共6个疗程，以用药前后测定的Kupperman评分、血促卵泡激素（FSH）、雌二醇（E₂）、促黄体激素（LH）及子宫内膜厚度作为评价指标。结果 随着用药时间的延长，患者更年期症状逐渐缓解，Kupperman评分总分不断下降，至用药6个疗程时，主要症状完全缓解，Kupperman评分总分下降95.0%（P<0.01），血FSH显著下降（P<0.05），E₂显著升高（P<0.01），LH水平明显下降（P<0.01），子宫内膜厚度无明显变化（P>0.05）。结论 芬吗通连续序贯治疗能有效缓解女性更年期症状，较好地控制月经周期和内分泌水平，且对子宫内膜无过度刺激。

Clinical effects of continuous sequential therapy of femoston in 121 cases of menopausal syndrome

Objective To explore the clinical efficacy and safety of continuous sequential hormone replacement therapy of femoston for menopausal syndrome. Methods 121 cases of menopausal syndrome at expert outpatient service in our hospital from January 2014 to October 2015 received hormone replacement therapy of femoston for 24 weeks. Before and after treatment, Kupperman score, blood follicle stimulating hormone (FSH), estradiol (E₂), luteinizing hormone (LH) and endometrial thickness were determined. Results With the prolonging of treatment time, patient''s menopausal symptoms gradually relieved. Kupperman scores were declining. After 6 courses of treatment, patient''s menopausal symptoms completely eased. Kupperman scores decreased by 95.0% (P<0.01), serum FSH and LH decreased significantly (P < 0.05 and P < 0.01) and serum E₂ increased notably (P<0.01) without endometrial thickness changes (P>0.05). Conclusion Continuous sequential therapy of femoston can effectively relieve menopausal syndrome and control the menstrual cycle and the endocrine level without stimulating the endometrium excessively.